Validation of Protein Biomarkers to Advance the Management of Autoimmune Disorders

David S. Gibson, Sorcha Finnegan, Stephen R. Pennington, Ji Qiu, Joshua LaBaer, Madeleine E. Rooney, Mark W. Duncan

    Research output: Chapter in Book/Report/Conference proceedingChapter

    276 Citations (Scopus)

    Abstract

    Despite the anticipated boom stemming from proteomic investigations, the rate at whichnovel protein biomarkers are introduced into clinical practice has remained static over thepast 20 years. The reality is that approaches to both discover and validate proteinbiomarkers remain inadequate, and consequently, many areas of medicine, including thebroad field of autoimmune disorders, remain deprived of the tools essential for the optimalmanagement of patients. Most importantly, there is a huge backlog of candidate biomarkersthat are yet to undergo thorough investigation and validation to assess their clinical utility.A recent assessment of the situation has estimated that although many tens of thousands ofpublications claim biomarker discoveries, there are roughly only 100 routinely used inclinical practice (Poste, 2011).This chapter reviews the potential applications of protein biomarkers to manageautoimmune diseases with a special focus on the transition from the biomarker discoverythrough to validation phases using proteomic strategies. We emphasize the importance ofcareful review of the discovery data, the critical roles of protein isoform verification, and theessential features of targeted and thorough validation. Ultimately, when these factors areappropriately considered and implemented, we are optimistic that autoimmune disorderscan be transformed by omics technologies and personalized practice can become a reality.
    LanguageEnglish
    Title of host publicationAutoimmune Disorders - Current Concepts and Advances from Bedside to Mechanistic Insights
    Place of PublicationCroatia/online
    Pages1-29
    VolumeChapte
    DOIs
    Publication statusPublished - 14 Nov 2011

    Fingerprint

    Biomarkers
    Proteomics
    Proteins
    Protein Isoforms
    Medicine
    Technology

    Keywords

    • Proteomics
    • Autoimmune disorders
    • biomarkers
    • mass spectrometry
    • protein arrays

    Cite this

    Gibson, D. S., Finnegan, S., Pennington, S. R., Qiu, J., LaBaer, J., Rooney, M. E., & Duncan, M. W. (2011). Validation of Protein Biomarkers to Advance the Management of Autoimmune Disorders. In Autoimmune Disorders - Current Concepts and Advances from Bedside to Mechanistic Insights (Vol. Chapte, pp. 1-29). Croatia/online. https://doi.org/10.5772/20908
    Gibson, David S. ; Finnegan, Sorcha ; Pennington, Stephen R. ; Qiu, Ji ; LaBaer, Joshua ; Rooney, Madeleine E. ; Duncan, Mark W. / Validation of Protein Biomarkers to Advance the Management of Autoimmune Disorders. Autoimmune Disorders - Current Concepts and Advances from Bedside to Mechanistic Insights. Vol. Chapte Croatia/online, 2011. pp. 1-29
    @inbook{6c3b9df106c24dfd924f70258694c0bd,
    title = "Validation of Protein Biomarkers to Advance the Management of Autoimmune Disorders",
    abstract = "Despite the anticipated boom stemming from proteomic investigations, the rate at whichnovel protein biomarkers are introduced into clinical practice has remained static over thepast 20 years. The reality is that approaches to both discover and validate proteinbiomarkers remain inadequate, and consequently, many areas of medicine, including thebroad field of autoimmune disorders, remain deprived of the tools essential for the optimalmanagement of patients. Most importantly, there is a huge backlog of candidate biomarkersthat are yet to undergo thorough investigation and validation to assess their clinical utility.A recent assessment of the situation has estimated that although many tens of thousands ofpublications claim biomarker discoveries, there are roughly only 100 routinely used inclinical practice (Poste, 2011).This chapter reviews the potential applications of protein biomarkers to manageautoimmune diseases with a special focus on the transition from the biomarker discoverythrough to validation phases using proteomic strategies. We emphasize the importance ofcareful review of the discovery data, the critical roles of protein isoform verification, and theessential features of targeted and thorough validation. Ultimately, when these factors areappropriately considered and implemented, we are optimistic that autoimmune disorderscan be transformed by omics technologies and personalized practice can become a reality.",
    keywords = "Proteomics, Autoimmune disorders, biomarkers, mass spectrometry, protein arrays",
    author = "Gibson, {David S.} and Sorcha Finnegan and Pennington, {Stephen R.} and Ji Qiu and Joshua LaBaer and Rooney, {Madeleine E.} and Duncan, {Mark W.}",
    year = "2011",
    month = "11",
    day = "14",
    doi = "10.5772/20908",
    language = "English",
    isbn = "ISBN 978-953-307-653-9",
    volume = "Chapte",
    pages = "1--29",
    booktitle = "Autoimmune Disorders - Current Concepts and Advances from Bedside to Mechanistic Insights",

    }

    Gibson, DS, Finnegan, S, Pennington, SR, Qiu, J, LaBaer, J, Rooney, ME & Duncan, MW 2011, Validation of Protein Biomarkers to Advance the Management of Autoimmune Disorders. in Autoimmune Disorders - Current Concepts and Advances from Bedside to Mechanistic Insights. vol. Chapte, Croatia/online, pp. 1-29. https://doi.org/10.5772/20908

    Validation of Protein Biomarkers to Advance the Management of Autoimmune Disorders. / Gibson, David S.; Finnegan, Sorcha; Pennington, Stephen R.; Qiu, Ji; LaBaer, Joshua; Rooney, Madeleine E.; Duncan, Mark W.

    Autoimmune Disorders - Current Concepts and Advances from Bedside to Mechanistic Insights. Vol. Chapte Croatia/online, 2011. p. 1-29.

    Research output: Chapter in Book/Report/Conference proceedingChapter

    TY - CHAP

    T1 - Validation of Protein Biomarkers to Advance the Management of Autoimmune Disorders

    AU - Gibson, David S.

    AU - Finnegan, Sorcha

    AU - Pennington, Stephen R.

    AU - Qiu, Ji

    AU - LaBaer, Joshua

    AU - Rooney, Madeleine E.

    AU - Duncan, Mark W.

    PY - 2011/11/14

    Y1 - 2011/11/14

    N2 - Despite the anticipated boom stemming from proteomic investigations, the rate at whichnovel protein biomarkers are introduced into clinical practice has remained static over thepast 20 years. The reality is that approaches to both discover and validate proteinbiomarkers remain inadequate, and consequently, many areas of medicine, including thebroad field of autoimmune disorders, remain deprived of the tools essential for the optimalmanagement of patients. Most importantly, there is a huge backlog of candidate biomarkersthat are yet to undergo thorough investigation and validation to assess their clinical utility.A recent assessment of the situation has estimated that although many tens of thousands ofpublications claim biomarker discoveries, there are roughly only 100 routinely used inclinical practice (Poste, 2011).This chapter reviews the potential applications of protein biomarkers to manageautoimmune diseases with a special focus on the transition from the biomarker discoverythrough to validation phases using proteomic strategies. We emphasize the importance ofcareful review of the discovery data, the critical roles of protein isoform verification, and theessential features of targeted and thorough validation. Ultimately, when these factors areappropriately considered and implemented, we are optimistic that autoimmune disorderscan be transformed by omics technologies and personalized practice can become a reality.

    AB - Despite the anticipated boom stemming from proteomic investigations, the rate at whichnovel protein biomarkers are introduced into clinical practice has remained static over thepast 20 years. The reality is that approaches to both discover and validate proteinbiomarkers remain inadequate, and consequently, many areas of medicine, including thebroad field of autoimmune disorders, remain deprived of the tools essential for the optimalmanagement of patients. Most importantly, there is a huge backlog of candidate biomarkersthat are yet to undergo thorough investigation and validation to assess their clinical utility.A recent assessment of the situation has estimated that although many tens of thousands ofpublications claim biomarker discoveries, there are roughly only 100 routinely used inclinical practice (Poste, 2011).This chapter reviews the potential applications of protein biomarkers to manageautoimmune diseases with a special focus on the transition from the biomarker discoverythrough to validation phases using proteomic strategies. We emphasize the importance ofcareful review of the discovery data, the critical roles of protein isoform verification, and theessential features of targeted and thorough validation. Ultimately, when these factors areappropriately considered and implemented, we are optimistic that autoimmune disorderscan be transformed by omics technologies and personalized practice can become a reality.

    KW - Proteomics

    KW - Autoimmune disorders

    KW - biomarkers

    KW - mass spectrometry

    KW - protein arrays

    U2 - 10.5772/20908

    DO - 10.5772/20908

    M3 - Chapter

    SN - ISBN 978-953-307-653-9

    VL - Chapte

    SP - 1

    EP - 29

    BT - Autoimmune Disorders - Current Concepts and Advances from Bedside to Mechanistic Insights

    CY - Croatia/online

    ER -

    Gibson DS, Finnegan S, Pennington SR, Qiu J, LaBaer J, Rooney ME et al. Validation of Protein Biomarkers to Advance the Management of Autoimmune Disorders. In Autoimmune Disorders - Current Concepts and Advances from Bedside to Mechanistic Insights. Vol. Chapte. Croatia/online. 2011. p. 1-29 https://doi.org/10.5772/20908